The FDA has approved brentuximab vedotin (Adcetris) to treat adults with previously untreated stage III or IV cHL, in combination with chemotherapy.
Recent FDA approval of front-line brentuximab vedotin with chemotherapy in patients with stage III/IV Hodgkin lymphoma offers the first new treatment for this disease in over 40 years.
Researchers report that PD-1/PD-L1 monoclonal blocking antibody allows T cells to remain active and fight malignant evolution, subsequently preventing tumor resistance.
A recent study found that Hodgkin lymphoma patients with active disease achieved clinical responses with tumor-specific T cells that were genetically modified to be rendered resistant to transforming growth factor beta, a cytokine expressed by most human cancers.
In this video reviews the management of nodular lymphocyte-predominant Hodgkin lymphoma.
Patients with Hodgkin lymphoma treated with a drug combination including brentuximab vedotin achieved superior progression-free survival, with a reduction in the risk for progression, death, or need for additional anticancer therapy, compared with the standard four-drug chemotherapy regimen.
In those with DLBCL, Burkitt lymphoma, and Hodgkin lymphoma, cure is often achieved. Furthermore, in the salvage setting, whether auto-HCT or allo-HCT is used, the same appears to be true. A great deal of progress has been made in the treatment of lymphoma in patients with HIV infection, but more remains to be done before outcomes are comparable to those of the general population.
Use of two BEACOPP regimens that incorporated brentuximab resulted in improved rates of complete response and complete remission at the end of treatment.
A new study found that Hodgkin lymphoma patients treated with consolidative proton therapy after chemotherapy had “excellent” early relapse-free survival rates and no early grade 3 radiation-related toxicities.
There is a high economic burden associated with the treatment of relapsed or refractory Hodgkin lymphoma. A recent study found that patients undergoing treatment for the disease incurred a median total all-cause cost of about $300,000.